SCHEMBL5085550

SCHEMBL5085550

Cc1ccc2c(O)c([N+](=O)[O-])c(=O)oc2c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.51
RAB9A P51151 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MCL1 Q07820 1/20 0.45
NQO1 P15559 1/20 0.44
PIM1 P11309 1/20 0.43
DYRK1A Q13627 1/20 0.43
PIM3 Q86V86 1/20 0.43
PIM2 Q9P1W9 1/20 0.43
HSD17B3 P37058 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.42
MAOB P27338 2/20 0.42
MAOA P21397 1/20 0.42
HTT P42858 1/20 0.41
CDC25A P30304 1/20 0.41
CDC25C P30307 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11388031 0.88 NQO1 (0.58) MAPK1RAB9AALDH1A1NQO1CA12
SCHEMBL11848796 0.85 NQO1 (0.56) ALDH1A1NQO1HSD17B3CA12CA9
SCHEMBL11390970 0.83 NQO1 (0.58) MAPK1RAB9AALDH1A1MCL1NQO1
SCHEMBL11848821 0.82 GRIN2D (0.55) NQO1CA12CA9MAPTLMNA
SCHEMBL11839557 0.82 CA12 (0.46) RAB9ANQO1CA12CA9MAPT
SCHEMBL12958024 0.82 LMNA (0.64) MAPK1RAB9AALDH1A1MCL1MAPT
SCHEMBL11848511 0.82 NQO1 (0.56) MAPK1RAB9AALDH1A1MCL1NQO1
SCHEMBL11848522 0.82 NQO1 (0.56) MAPK1RAB9AALDH1A1MCL1NQO1
SCHEMBL11462850 0.82 MAOB (0.47) RAB9AALDH1A1NQO1MAOB
SCHEMBL11563063 0.82 NQO1 (0.61) RAB9AALDH1A1NQO1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120774-B2 Novobiocin analogues having modified sugar moieties UNIVERSITY OF KANSAS (US) 2015-09-01 US disclosed
US-20120252745-A1 NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-10-04 US disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 MAPK1 2791/4885RAB9A 3126/4885ALDH1A1 2000/4885
US-20120252745-A1 NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES HSP90AB1, HSP90AB2P, HSP90B1 MAPK1 785/4885RAB9A 3026/4885ALDH1A1 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.